Latest Breaking News On - Paul sagan - Page 11 : comparemela.com

Visus Therapeutics to Present at 2023 JMP Securities Life Science Conference

Visus Therapeutics to Present at 2023 JMP Securities Life Science Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Ben bergoPaul saganMichele grayJames heinsBusiness biotechCompany announced positive topline clinical dataVisus therapeutics incEye care tradeAnnounced positive topline clinical dataTherapeutics incLife science conferenceNew york hiltonVisus therapeutics

Visus Therapeutics Presents Topline Clinical Data from Phase 3 Pivotal BRIO-I Trial of BRIMOCHOL™ PF for the Treatment of Presbyopia at Eyecelerator @ ASCRS 2023

Press Release Visus Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapies for indications in the front and back of the eye, today presented key topline data from the pivotal Phase 3 BRIO-I clinical trial….

United kingdomUnited statesPaul saganMichele grayBen bergoAlmamoun abdelkaderHerb kaufmanApril dovoranyVisus therapeutics incUs census bureauPopulation divisionEye care tradeDrug administrationBusiness biotechReported outcome measuresTherapeutics inc

EQS-News: Newron announces Senior Management Team changes

EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Personnel Newron announces Senior Management Team changes 02.05.2023 / .

Kyongsang buktoSouth koreaUnited arab emiratesUnited statesUnited kingdomAnne hennecke caroline bergmannPaul saganMarco caremiValentin handschinStefan weberLaura faravelliRoberto galliMc servicesSenior management teamSenior management team at newronBusiness development

Visus Therapeutics Announces Positive Topline Clinical Data from Phase 3 Pivotal BRIO-I Trial of BRIMOCHOL PF™ for the Treatment of Presbyopia

Press Release Visus Therapeutics Inc., a clinical-stage pharmaceutical company, focused on developing multi-targeted ophthalmic therapies for indications in the front and back of the eye, today reported positive topline results from its Phase 3 pivotal BRIO-I trial….

United statesSan diegoMichele grayApril dovoranyEric donnenfeldRhett schiffmanPaul saganVisus therapeutics incEye care tradeUs census bureauPopulation divisionBusiness biotechAmerican society of cataractCompany medical advisory boardUnited kingdomTherapeutics inc

Newron Pharmaceuticals S p A : Newron Presents Six-Month Interim Data From the First 100 Patients Randomized in Study 014/015 at the 31st European Congress of Psychiatry

Study 014/015 is a Phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia (TRS) Full data suggest a new strategy for the management of TRS patients

United kingdomFrance generalUnited statesKyongsang buktoSouth koreaUnited arab emiratesSri lankaPaul saganStefan weberAnne hennecke caroline bergmannValentin handschinEuropean unionMc servicesEuropean congressNewron pharmaceuticalsSupernus pharmaceuticals